Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
1(17%)

Phase Distribution

Ph not_applicable
1
17%
Ph phase_2
2
33%
Ph early_phase_1
2
33%

Phase Distribution

2

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Early Phase 1First-in-human
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(3)
Terminated(1)
Other(2)

Detailed Status

Completed3
unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 12 (40.0%)
Phase 22 (40.0%)
N/A1 (20.0%)

Trials by Status

completed350%
terminated117%
unknown233%

Recent Activity

0 active trials
Showing 5 of 6
completednot_applicable

Efficacy and Safety of COVID-19 Convalescent Plasma

NCT04397523
completedphase_2

Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients

NCT04354831
completedearly_phase_1

COVID-19 Convalescent Plasma

NCT04340050
unknown

Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)

NCT04360486
terminatedphase_2

Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19

NCT04567173
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04397523Not Applicable

Efficacy and Safety of COVID-19 Convalescent Plasma

Completed
NCT04354831Phase 2

Efficacy and Safety of Convalescent Plasma in Treating COVID-19 Hospitalized Patients

Completed
NCT04340050Early Phase 1

COVID-19 Convalescent Plasma

Completed
NCT04360486

Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)

Unknown
NCT04567173Phase 2

Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19

Terminated
NCT04345679Early Phase 1

Anti COVID-19 Convalescent Plasma Therapy

Unknown

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6